Reata Pharmaceuticals Announces First Quarter 2018 Financial Results and an Update on Development Programs

Reata Pharmaceuticals (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today provided an update on the Company’s product development programs and announced financial results for the first quarter ended March 31, 2018.

As quoted in the press release:

We are completing enrollment earlier than planned in the autosomal dominant polycystic kidney disease (ADPKD), IgA nephropathy, and type 1 diabetic CKD (T1D CKD) cohorts of PHOENIX.  We expect enrollment in all three cohorts to be complete by the end of May and full primary endpoint data from these three rare forms of CKD to be available during the third quarter of 2018.  Full primary endpoint data from the focal segmental glomerulosclerosis cohort are expected to be available in the first half of 2019.

Interim data for the ADPKD and IgA nephropathy cohorts will be presented in a late-breaking abstract at the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) meeting in Copenhagen on May 25, 2018 in an abstract entitled “Initial Results from a Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy.”

Click here to read the full press release.